Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23 June 2014
takeda-logo-big

Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502) has updated on the third-party surrounding the results of the CASE-J study,  a clinical study related to the hypertension drug Blopress (candesartan cilexetil), namely “potential involvement in data analysis and data falsification,” “potential conflicts of interest,” and “inappropriate promotional activities.”

While the results of the internal investigation did not confirm “data falsification” or “possible conflicts of interest,” it was found that “a portion of promotional activities were inappropriate" in their use of the CASE-J study results.” Takeda explained this and apologized to patients and health care professionals. Furthermore, as a continuation of the internal investigation, Takeda announced the appointment of the law firm Jones Day as a third-party organization to conduct an investigation to address points that were insufficiently clear.

Over the course of the three-month Jones Day investigation, Takeda has not issued objections to any part of the methods or scope as specified, and has been fully cooperating with the investigation. In accordance with this, the drugmaker has received Jones Day's statement that their independence has not been jeopardized throughout the process of the investigation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical